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Background: The transcription factors NFATc1 and PU.1 play important roles in osteoclast development.
NFATc1 and PU.1 transactivate osteoclast-speciﬁc gene expression and a deﬁciency in NFATc1 or PU.1
genes causes osteopetrosis due to an insufﬁcient development of osteoclasts. However, the existence of
cross-regulation between NFATc1 and PU.1 is largely unknown. In the present study, the role of PU.1 in
NFATc1 expression was investigated.
Methods: Osteoclasts were generated from mouse bone marrow cells. PU.1 knockdown was performed
with siRNA introduction. The mRNA levels in siRNA-introduced cells were determined by quantitative
RT-PCR. The involvement of PU.1 in the NFATc1 promoter was analyzed by using a chromatin immu-
noprecipitation (ChIP) assay and a reporter assay. Retrovirus vector was used for enforced expression of
PU.1.
Results: Introduction of PU.1 siRNA into bone marrow-derived osteoclasts resulted in a decrease in
NFATc1 mRNA level. A ChIP assay showed that PU.1 bound to the NFATc1 promoter in osteoclasts. NFATc1
promoter activity was reduced in PU.1 knockdown cells as assessed by a reporter assay. PU.1 siRNA
introduction also downregulated the expression of osteoclast-speciﬁc genes and tartrate resistant acid
phosphatase (TRAP) activity. Enforced expression of PU.1 using a retrovirus vector increased NFATc1
expression and TRAP activity. When NFATc1 expression was knocked down by using siRNA, the induction
of osteoclast-speciﬁc genes and TRAP-positive cells was suppressed without affecting the expression
level of PU.1.
Conclusions: These results indicate that PU.1 is involved in osteoclast development by transactivating
NFATc1 expression via direct binding to the NFATc1 promoter.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The transcription factor NFATc1 is a master regulator for the
development and speciﬁc gene expression of osteoclasts. The Ets-
family transcription factor PU.1, which plays important roles in
the development of hematopoietic lineages, especially the mono-
cyte/dendritic cell-lineage, is involved in osteoclast-speciﬁc geneal Science and Technology,
University of Science, 6-3-1
).
ety of Allergology.
rgology. Production and hosting by Elseexpression with NFATc1.1e3 The requirement for NFATc1 and PU.1
for osteoclast development has been observed in in vitro experi-
ments. However, little is known about their roles in vivo in the
function of osteoclastogenesis, because gene-targeted disruption of
NFATc1 results in embryonic lethality4; moreover, PU.1 knockout
mice are embryonic lethal5 or die of severe septicemia within 48 h
after birth,6 and these mice also exhibit osteopetrosis.7 It is largely
unknown if PU.1 plays a role in NFATc1 expression, although it has
been frequently observed that NFATc1 and PU.1 cooperatively
transactivate the promoters of cell-type speciﬁc genes in osteo-
clasts. In the present study, considering that osteoclasts aremyeloid
organ and develop from a monocytic precursor and that PU.1 is
important for the development of the monocyte/dendritic cellvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Effect of PU.1 siRNA on NFATc1 mRNA level in osteoclasts. PU.1 siRNA or control
siRNA was introduced into BM-derived osteoclasts on day 0 and day þ3 by using
lipofectamine (A) or on day 0 by electroporation (B), and the cells were harvested on
day þ4 for analysis of mRNA levels. The mRNA expression level of PU.1 and NFATc1 in
the cells is displayed as the ratio of mRNA levels versus those in control siRNA-
introduced cells. Data represent means ± SEM of four (A) or three (B) independent
experiments. *p < 0.05.
Fig. 2. Effect of PU.1 siRNA on NFATc1 promoter activity. A luciferase-linked NFATc1 promote
was introduced into the cells with reporter plasmids and luciferase activity was assayed. Rel
cells transfected with the control pGL4-Basic plasmid. Data represent means ± SEM of thre
K. Ishiyama et al. / Allergology International 64 (2015) 241e247242lineage, we hypothesized and investigated the possibility that PU.1
regulates the NFATc1 promoter in osteoclasts.Methods
Mice
BALB/c mice were purchased from Japan SLC (Hamamatsu,
Japan). All animal experiments were approved by the Juntendo
University Animal Experimental Ethics Committee and by the
Tokyo University of Science Animal Experimental Ethics Committee
and complied with National Institutes of Health guidelines for an-
imal care.Cells
Whole bonemarrow (BM) cells from BALB/c micewere grown in
a-MEM medium (GIBCO, Grand Island, NY, USA) supplemented
with 10% heat-inactivated FBS (SigmaeAldrich, St. Louis, MO, USA),
100 mM 2-mercaptoethanol, 10 mM MEM nonessential amino acids
(SigmaeAldrich), 100 U/ml penicillin, 100 mg/ml streptomycin, and
50 ng/ml recombinant murine (rm) M-CSF (PeproTech, London,
United Kingdom) for 3 days (from day 3 to day 0). The resulting
adherent osteoclast precursors were cultured in the presence of
50 ng/ml rmM-CSF and 100 ng/ml recombinant human (rh) RANKL
(PeproTech) for an additional 3e8 days (from day 0 to day-
þ3 ~ day þ8). The mouse monocytic cell line RAW264.7 was
maintained in RPMI 1640 medium (SigmaeAldrich) supplemented
with 10% heat-inactivated FBS and penicillin/streptomycin.Knockdown of PU.1 expression by siRNA
PU.1 siRNA (Stealth Select RNAi, Sfpi1-MSS247676), NFATc1
siRNA [Stealth Select RNAi, Nfatc1-MSS275981 (#1) and Nfatc1-
MSS275982 (#2)] and control siRNA (Stealth Negative Universal
Control, no. 45-2001) were purchased from Invitrogen (Carlsbad,
CA, USA). A 5-ml of aliquot of 20 mM siRNAwas introduced into BM-
derived developing osteoclast cells using Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer's instructions. Electro-
poration was also used to introduce siRNAs into osteoclast cells as
follows. A 2.5-ml of aliquot of 20 mM siRNA was introduced into
1  106 cells using a Mouse Macrophage Nucleofector kit (Lonza,
Basel, Switzerland) with a Nucleofector II (Lonza) set at Y-001.r-driven pGL4 plasmid was transfected into RAW264.7 cells. PU.1 siRNA or control siRNA
ative luciferase activity is displayed as the ratio of luciferase activity versus that seen in
e independent experiments. *p < 0.05.
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Total RNA prepared from cells with an RNeasy kit (QIAGEN,
Hilden, Germany) was reverse transcribed using a High Capacity
cDNA Reverse Transcription kit (Applied Biosystems, Foster City,
CA, USA). The mRNA level of PU.1, NFATc1, Ctsk, Oscar, Acp5, Itgb3,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
quantiﬁed by using a Step-One Real-Time PCR system (Applied
Biosystems) with TaqMan Gene Expression Assays (AppliedFig. 3. PU.1 binds to the NFATc1 promoter in osteoclasts. Chromosomal DNA of BM-
derived osteoclasts (day þ8) was immunoprecipitated with control IgG (open bars)
or anti-PU.1 Ab (closed bars) and analyzed for the NFATc1 promoter using quantitative
real-time PCR. The results are expressed as means ± SEM of three independent ex-
periments (top). The results of three experiments performed triplicate samples were
also shown (bottom). *p < 0.05.Biosystems: no. Mm01270606_m1 for PU.1, Mm00479445_m1 for
NFATc1, Mm00484039_m1 for Ctsk, Mm00558665_m1 for Oscar,
Mm00475698_m1 for Acp5, Mm00443980_m1 for Itgb3, and
mouse GAPDH no. 44352339) and TaqMan Universal Master Mix
(Applied Biosystems). The expression level of each mRNA was
evaluated relative to that of GAPDH as described previously.8,9
Luciferase reporter assay
To generate reporter plasmids, 5’-ﬂanking regions of the mouse
NFATc1 gene (843/þ29, or 458/þ29) were introduced into the
pGL4-Basic vector (Promega, Madison, WI, USA) by using PCR andFig. 4. Effect of PU.1 siRNA on osteoclast-speciﬁc gene expression and function. PU.1
siRNA or control siRNA was introduced into BM-derived cells on day 0, and day þ3 by
using the lipofectamine method (A top), or on day 0 by electroporation (A bottom), and
cells were harvested on day þ8 for analysis of mRNA levels (A) or for TRAP staining (B).
The mRNA expression level of PU.1, NFATc1, Ctsk, Oscar, Acp5, and Itgb3 in BM-derived
osteoclasts was analyzed using quantitative RT-PCR and is displayed as the ratio of
mRNA levels versus those seen in control siRNA-introduced cells. Data represent
means ± SEM of three independent experiments (A) or means ± SD of three inde-
pendent experiments (B). *p < 0.05.
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sequences of synthesized oligonucleotides that were used as
primers are listed in Supplementary Table 1. Transfection of
RAW264.7 cells and determination of luciferase activity were per-
formed as described previously.8,10
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as described previously using the
BM-derived osteoclasts on day 8.8,11 Anti-PU.1 goat IgG (D-19, no.
sc-5949, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and goat
IgG (no. 02-6202, Invitrogen) were used. The amount of chromo-
somal DNA including the NFATc1 promoter was determined by the
quantitative real-time PCR system using the primers listed in
Supplementary Table 2. The ratio of immunoprecipitated DNA was
calculated as described previously.10
Tartrate resistant acid phosphatase (TRAP) staining
TRAP activity of osteoclasts was determined as follows. Cells
cultured in 24 wells-plates were ﬁxed with 500 ml of 10% formalde-
hyde/PBS for 10 min after washing with PBS, and were then, rinsed
with acetone/ethanol (1:1) for 0.5e1min. After drying, the cellswere
incubated in 200 ml of TRAP solution (30mgof the Dye Fast red violet
LB salt, SigmaeAldrich) that was dissolved in 50ml of buffer (50 nM
sodium tartrate, 0.1 M sodium acetate, pH 5.0) containing 5 mg
naphthol AS-MXphosphate (SigmaeAldrich) pre-dissolved in 0.5ml
formamide) for 10 min and washed with distilled water.
Introduction of PU.1 cDNA into osteoclast cells using a retrovirus vector
Retroviral infection of BM-osteoclasts was performed according
to a previously reported method.12 Full-length mouse PU.1 cDNAFig. 5. Effect of enforced expression of PU.1 using a retroviral vector on the mRNA express
day 2, and GFP-positive transfectants were sorted on day 0. Cells were harvested on daywas ampliﬁed by PCR using following oligonucleotides as primers:
PU.1 EcoRI-forward; 5’-aggagaattcgttacaggcgtgcaaaatgg-30, and
PU.1 SalI-reverse; 50-catggtcgactcagtggggcgggaggcgcc-30 (the
recognition sequences of EcoRI and SalI are shown in italic, and the
initiation and termination codons are underlined) and Balb/c
mouse BM-derived dendritic cell cDNA as a template. The ampliﬁed
cDNA was inserted into the EcoRI/SalI site of p3xFlagCMV7.1 (Invi-
trogen). After conﬁrmation of the nucleotide sequence, the BglII/
SalI DNA fragment encoding mouse PU.1 tagged with 3 Flag se-
quences (3xFlag) at the N-terminus was excised from
p3xFlagCMV7.1-mPU.1 and re-ligated into the BglII/SalI-digested
pMXs-IG plasmid12 to generate pMXs-IG-3xFlag-mPU.1. Plasmids
pMXs-IG (mock vector) and pMXs-IG-3xFlag-mPU.1 were tran-
siently introduced into Plat-E packaging cells to obtain infectious
viruses as described previously.12 BM-derived cells were infected
with retrovirus on day 2, and GFP-positive transfectants were
sorted on day 0 by using JSAN (Bay Bioscience, Hyogo, Japan).
Statistical analysis
Statistical analysis was performed using a two-tailed Student's
t-test with p values <0.05 considered signiﬁcant.
Results and discussion
Effect of PU.1 siRNA on the NFATc1 mRNA level in osteoclast
PU.1 siRNA that was previously used for speciﬁc knockdown of
PU.1 mRNA,10,12 was introduced into mouse BM-derived osteo-
clasts. Although the PU.1 mRNA knockdown level was moderate in
comparison with that obtained in our previous studies using BM-
dendritic cells (DCs),10,12 the level of PU.1 mRNA in osteoclasts
was signiﬁcantly reduced by introduction of PU.1 siRNA either byion of NFATc1 and on TRAP activity. BM-derived cells were infected with retrovirus on
þ6 for analysis of mRNA levels (A) or for TRAP staining (B, C). *p < 0.05.
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method (Fig. 1B). Under these experimental conditions, we found
that the NFATc1 mRNA level in PU.1 siRNA-introduced cells was
lower than that of cells with control siRNA, indicating that the
amount of PU.1 affects the NFATc1 transcriptional level.
Effect of PU.1 siRNA on NFATc1 promoter activity
The reduction in BM-derived osteoclast NFATc1 mRNA level
resulting from the introduction of PU.1 siRNA (Fig. 1) suggested that
PU.1 is involved in the transcription of the NFATc1 gene. To evaluate
the effects of PU.1 on NFATc1 promoter activity, we performed a
reporter assay using a luciferase-linked NFATc1 promoter trans-
fected into the RAW264.7 cell line, which is amurinemonocytic cell
line that was previously shown to be useful for evaluation of PU.1-
mediated gene expression.10 Luciferase assays showed that the
NFATc1 promoter exhibited signiﬁcant transcriptional activity
when transfected into RAW267.4 cells, as shown in Fig. 2. When
PU.1 siRNA was introduced into RAW267.4 cells with the reporter
plasmid, the luciferase activity driven by the NFATc1 promoter
decreased, whereas luciferase activity of the transfected control
pGL4-Basic plasmid was not reduced by transfection of PU.1 siRNA.
These results suggest that the PU.1 expression level is positively
associated with NFATc1 promoter activity.Fig. 6. Effect of NFATc1 siRNA on osteoclast-speciﬁc gene expression and function. NFATc1 si
and cells were harvested on day þ6. A. PU.1 mRNA levels in NFATc1 siRNA-introduced cells. P
*p < 0.05. B. The mRNA expression level of osteoclast-speciﬁc genes in NFATc1 siRNA-introPU.1 binds to the NFATc1 promoter in osteoclasts
Knockdown of PU.1 reduced NFATc1 mRNA levels and down-
regulated NFATc1 promoter activity. To determine whether PU.1
directly associates with the NFATc1 promoter region in chromo-
somes, a ChIP assay was performed using the BM-derived osteo-
clasts. As shown in Fig. 3, amarkedly higheramountof chromosomal
DNA containing the NFATc1 promoter was immunoprecipitated
with the anti-PU.1 Ab compared with control IgG. This result in-
dicates that PU.1 binds to theNFATc1 promoter region in osteoclasts.
PU.1 knockdown by siRNA suppresses the generation of osteoclasts
We then determined the effect of PU.1 knockdown using siRNA
on the expression of osteoclast-speciﬁc genes, which we assayed
using quantitative real-time PCR. A decrease in NFATc1 mRNA level
was observed when the PU.1 mRNA level was reduced to approxi-
mately 30% of that of control cells on day 8. Under this experi-
mental condition, the mRNA levels of osteoclast-speciﬁc genes,
including Ctsk, Oscar, Acp5, and Itg3 were signiﬁcantly decreased
compared to control siRNA-transfected cells (Fig. 4A). The number
of TRAP positively stained cells was also reduced by PU.1 siRNA-
transfection (Fig. 4B). These results indicate that PU.1 knockdown
by siRNA suppresses osteoclastogenesis.RNA or control siRNA was introduced into BM-derived cells on day 0 by electroporation
U.1 siRNA-introduced cells prepared in the same experiment are shown to comparison.
duced cells. *p < 0.05. C. TRAP staining of NFATc1 siRNA-introduced cells.
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osteoclasts
To conﬁrm the involvement of PU.1 in the expression of NFATc1,
BM-derived cells were transfected with a retroviral vector carrying
mouse PU.1 cDNA. The PU.1 mRNA level in PU.1 retrovirus-
transfected cells was approximately 2-fold of that in mock trans-
fectants (Fig. 5A). Under this experimental condition of enforced
expression of PU.1, the NFATc1 mRNA level was signiﬁcantly upre-
gulated (Fig. 5A). TRAP staining showed that retroviral over-
expression of PU.1 increased the number of TRAP-positive cells
(Fig. 5B, C). These results suggest that enforced expression of PU.1
induces the expression of NFATc1 and subsequently accelerates the
development of osteoclasts.NFATc1 knockdown does not affect the expression of PU.1
Although the role of PU.1 in NFATc1 expression was studied in
the present study, it was unknown whether NFATc1 functions up-
stream of PU.1. Therefore, to evaluate the effect of NFATc1 knock-
down on the expression of PU.1 and osteoclastogenesis, BM-
derived cells were transfected with NFATc1 siRNA. Two different
siRNAs for NFATc1 were used to exclude the possibility of any off-
target effects of the siRNAs, Both siRNAs reduced the amount of
NFATc1 mRNA and the reduction was comparable to the reduction
in the amount of PU.1 mRNA in PU.1 siRNA-introduced cells
(Fig. 6A). Under this experimental condition, the PU.1 mRNA level
was not affected by the knockdown of NFATc1 (Fig. 6A), but theFig. 7. Schematic drawing of the role of PU.1 in the regulation of osteoclast-speciﬁc
genes. In the present study, we demonstrated that PU.1 is involved in the expression
of osteoclast-speciﬁc genes as a transcriptional activator of NFATc1 (shown with the
red arrow and box) in addition to the well-known role of PU.1 in the transactivation of
osteoclast-speciﬁc genes, including Ctsk, Acp5, and Itgb3, in cooperation manner with
NFATc1.expression level of mRNAs for some osteoclast-speciﬁc genes and
the number of TRAP-positive cells were reduced by NFATc1 siRNA
transfection (Fig. 6B, C). These results indicate that PU.1 expression
is not under the control of NFATc1 in osteoclasts, whereas, in
contrast, PU.1 plays a role as a positive regulator of NFATc1.
PU.1 is known to directly transactivate osteoclast-speciﬁc gen-
es.1e3,13e15 In the present study, we showed the possibility that PU.1
knockdown suppresses osteoclast-speciﬁc genes indirectly through
the repression of NFATc1 expression, in addition to a direct
repressive effect (shown as a schematic drawing in Fig. 7). We have
previously reported that PU.1 regulates the expression of MHC class
II,10 CD80 and CD86,12 and TNF-a16 in DCs, and the expression of
FcεRI in mast cells.17,18 The present study indicates that, in addition
to its effects on DCs and mast cells, PU.1-targeted knockdown
suppresses gene expression and function of osteoclasts.
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